$4.95
2.83%
Downside
Day's Volatility :5.69%
Upside
2.94%
10.91%
Downside
52 Weeks Volatility :83.79%
Upside
81.8%
Period | Agenus Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -70.18% | 5.1% | 0.0% |
6 Months | -64.7% | 4.9% | 0.0% |
1 Year | -80.36% | 16.6% | 0.0% |
3 Years | -96.13% | 13.2% | -22.3% |
Market Capitalization | 107.6M |
Book Value | - $11.42 |
Earnings Per Share (EPS) | -11.14 |
PEG Ratio | 0.0 |
Wall Street Target Price | 9.75 |
Profit Margin | -139.99% |
Operating Margin TTM | -128.43% |
Return On Assets TTM | -21.04% |
Return On Equity TTM | -1278.83% |
Revenue TTM | 159.6M |
Revenue Per Share TTM | 8.02 |
Quarterly Revenue Growth YOY | -7.1% |
Gross Profit TTM | 82.6M |
EBITDA | -99.0M |
Diluted Eps TTM | -11.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -10.3 |
EPS Estimate Next Year | -9.69 |
EPS Estimate Current Quarter | -1.44 |
EPS Estimate Next Quarter | -2.14 |
What analysts predicted
Upside of 96.97%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 36.8M | ↓ 14.21% |
Net Income | -159.7M | ↑ 32.31% |
Net Profit Margin | -434.14% | ↓ 152.66% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 150.0M | ↑ 307.92% |
Net Income | -149.1M | ↓ 6.61% |
Net Profit Margin | -99.39% | ↑ 334.75% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 88.2M | ↓ 41.24% |
Net Income | -240.1M | ↑ 61.02% |
Net Profit Margin | -272.35% | ↓ 172.96% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 295.7M | ↑ 235.34% |
Net Income | -94.7M | ↓ 60.57% |
Net Profit Margin | -32.03% | ↑ 240.32% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 98.0M | ↓ 66.85% |
Net Income | -271.5M | ↑ 186.72% |
Net Profit Margin | -276.99% | ↓ 244.96% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 156.3M | ↑ 59.47% |
Net Income | -245.8M | ↓ 9.49% |
Net Profit Margin | -157.22% | ↑ 119.77% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 22.9M | ↓ 19.32% |
Net Income | -67.8M | ↓ 30.34% |
Net Profit Margin | -296.25% | ↑ 46.87% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.3M | ↑ 10.45% |
Net Income | -73.4M | ↑ 8.23% |
Net Profit Margin | -290.28% | ↑ 5.97% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.3M | ↓ 3.88% |
Net Income | -62.2M | ↓ 15.29% |
Net Profit Margin | -255.82% | ↑ 34.46% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 83.8M | ↑ 244.66% |
Net Income | -46.3M | ↓ 25.58% |
Net Profit Margin | -55.24% | ↑ 200.58% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 28.0M | ↓ 66.58% |
Net Income | -61.9M | ↑ 33.69% |
Net Profit Margin | -220.98% | ↓ 165.74% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 23.5M | ↓ 16.05% |
Net Income | -53.1M | ↓ 14.23% |
Net Profit Margin | -225.79% | ↓ 4.81% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 136.4M | ↓ 1.45% |
Total Liabilities | 310.9M | ↑ 45.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 155.3M | ↑ 13.88% |
Total Liabilities | 386.7M | ↑ 24.35% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 214.5M | ↑ 38.1% |
Total Liabilities | 426.0M | ↑ 10.17% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 466.0M | ↑ 117.22% |
Total Liabilities | 418.0M | ↓ 1.87% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 413.6M | ↓ 11.25% |
Total Liabilities | 468.5M | ↑ 12.06% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 313.9M | ↓ 24.09% |
Total Liabilities | 462.3M | ↓ 1.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 412.9M | ↓ 0.17% |
Total Liabilities | 466.0M | ↓ 0.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 383.6M | ↓ 7.09% |
Total Liabilities | 460.4M | ↓ 1.2% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 335.5M | ↓ 12.54% |
Total Liabilities | 450.8M | ↓ 2.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 313.9M | ↓ 6.43% |
Total Liabilities | 462.3M | ↑ 2.56% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 256.6M | ↓ 18.27% |
Total Liabilities | 446.9M | ↓ 3.33% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 292.4M | ↑ 13.98% |
Total Liabilities | 513.3M | ↑ 14.85% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -131.1M | ↑ 39.13% |
Investing Cash Flow | -3.6M | ↓ 273.98% |
Financing Cash Flow | 128.3M | ↑ 59.28% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.7M | ↓ 85.75% |
Investing Cash Flow | -4.7M | ↑ 29.69% |
Financing Cash Flow | 31.3M | ↓ 75.58% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -139.1M | ↑ 644.55% |
Investing Cash Flow | -4.4M | ↓ 4.64% |
Financing Cash Flow | 183.9M | ↑ 486.96% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 10.1M | ↓ 107.29% |
Investing Cash Flow | -43.2M | ↑ 871.63% |
Financing Cash Flow | 225.3M | ↑ 22.52% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -175.4M | ↓ 1828.66% |
Investing Cash Flow | -33.6M | ↓ 22.11% |
Financing Cash Flow | 95.8M | ↓ 57.46% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -58.5M | ↑ 23.63% |
Investing Cash Flow | -11.5M | ↑ 79.99% |
Financing Cash Flow | 56.3M | ↑ 136.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.5M | ↓ 23.99% |
Investing Cash Flow | 517.0K | ↓ 104.5% |
Financing Cash Flow | 38.3M | ↓ 31.98% |
Sell
Neutral
Buy
Agenus Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Agenus Inc | -2.56% | -64.7% | -80.36% | -96.13% | -92.12% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Agenus Inc | 0.46 | NA | 0.0 | -10.3 | -12.79 | -0.21 | NA | -11.42 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Agenus Inc | Buy | $107.6M | -92.12% | 0.46 | -139.99% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Agenus Inc
Revenue is down for the last 3 quarters, 83.80M → 23.50M (in $), with an average decrease of 41.3% per quarter
Netprofit is up for the last 2 quarters, -61.88M → -53.08M (in $), with an average increase of 16.6% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 117.5%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 165.3%
Vanguard Group Inc
BlackRock Inc
Artal Group S A
Deep Track Capital, LP
Point72 Asset Management, L.P.
Charles Schwab Investment Management Inc
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Organization | Agenus Inc |
Employees | 389 |
CEO | Dr. Garo H. Armen Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.95
-1.0%
Keyarch Acquisition Corp
$4.95
-1.0%
Connexa Sports Technologies Inc
$4.95
-1.0%
Us Value Etf
$4.95
-1.0%
First Wave Biopharma Inc
$4.95
-1.0%
Global X Msci Next Emerging
$4.95
-1.0%
Fat Projects Acquisition Corp
$4.95
-1.0%
Capital Link Global Fintech
$4.95
-1.0%
Applied Uv Inc
$4.95
-1.0%